GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy [Seeking Alpha]
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Seeking Alpha
Shingrix and RSV vaccine sales in 2023 exceeded expectations and appear to show no sign of slowing down. GSK's franchise only faces minor patent cliffs over the next 5-10 years, supporting its long-term growth plan. I believe the ongoing Zantac litigation risk is overblown and that it will not be a key factor determining GSK's valuation in the long run. GSK overview GSK plc ( NYSE: GSK ) is a British multinational "Big Pharma" established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham. It possesses a leading position in the traditional vaccine (Not mRNA vaccine) and HIV area. In fact, GSK produced the first FDA-approved malaria vaccine. Currently, its best-selling vaccine is Shingrix for Shingles, which netted ~$4.33 billion in sales in 2023 and is rapidly growing still, as it just started to enter developing markets. On the other hand, GSK faces significant litigation risk as a result of its ongoing Zantac dispute. In this article, I will examine GSK's moat
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve [Seeking Alpha]Seeking Alpha
- 12 Best Biotech Penny Stocks to Invest In [Yahoo! Finance]Yahoo! Finance
- Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancerBusiness Wire
- GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising RiseBusiness Wire
- GSK plc (NYSE: GSK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.MarketBeat
GSK
Sec Filings
- 4/24/24 - Form 6-K
- 4/19/24 - Form 6-K
- 4/17/24 - Form 6-K
- GSK's page on the SEC website